Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  HIV Infection

  Free Subscription

Articles published in HIV Med

Retrieve available abstracts of 168 articles:
HTML format

Single Articles

    November 2021
  1. NAITO T, Suzuki M, Fukushima S, Yuda M, et al
    Comorbidities and co-medications among 28 089 people living with HIV: A nationwide cohort study from 2009 to 2019 in Japan.
    HIV Med. 2021 Nov 25. doi: 10.1111/hiv.13206.
    PubMed     Abstract available

  2. HAN WM, Law MG, Choi JY, Ditangco R, et al
    Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV.
    HIV Med. 2021 Nov 23. doi: 10.1111/hiv.13211.
    PubMed     Abstract available

  3. KADDU-MULINDWA D, Keuser L, Lesan V, Rissland J, et al
    IgG seroprevalence of COVID-19 among people living with HIV or at high risk of HIV in south-west Germany: A seroprevalence study.
    HIV Med. 2021 Nov 22. doi: 10.1111/hiv.13207.
    PubMed     Abstract available

  4. TARIQ S, Okhai H, Severn A, Sabin CA, et al
    Follicle-stimulating hormone in postmenopausal women living with HIV: a prevalence study.
    HIV Med. 2021 Nov 17. doi: 10.1111/hiv.13205.
    PubMed     Abstract available

  5. REYNOLDS Z, McCluskey SM, Moosa MYS, Gilbert RF, et al
    Who's slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first-line HIV treatment in Uganda and South Africa.
    HIV Med. 2021 Nov 9. doi: 10.1111/hiv.13203.
    PubMed     Abstract available

  6. CUZIN L, Delobel P, Martin-Blondel G
    Letter to the editor.
    HIV Med. 2021 Nov 7. doi: 10.1111/hiv.13192.

  7. O'NEIL PJ, Stafford KA, Ryscavage PA
    Assessing risk factors for hypertension in young adults with perinatally acquired HIV infection: A case-control study.
    HIV Med. 2021 Nov 2. doi: 10.1111/hiv.13199.
    PubMed     Abstract available

  8. SILVA-NASH J, Bordelon S, Searcy SA, Dare RK, et al
    Standardizing HIV post-exposure prophylaxis in the emergency department following sexual assault.
    HIV Med. 2021 Nov 2. doi: 10.1111/hiv.13196.
    PubMed     Abstract available

  9. JEDICKE N, Stankov MV, Cossmann A, Dopfer-Jablonka A, et al
    Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
    HIV Med. 2021 Nov 2. doi: 10.1111/hiv.13202.
    PubMed     Abstract available

  10. RICHARDSON D, Nichols K, Hughes R, Smith H, et al
    The characteristics of men who have sex with men (MSM) using post-exposure prophylaxis for sexual exposure (PEPSE) in the pre-exposure prophylaxis (PrEP) era.
    HIV Med. 2021 Nov 2. doi: 10.1111/hiv.13201.
    PubMed     Abstract available

    October 2021
  11. CASTILLO-MANCILLA JR, Musinguzi N, Asiimwe S, Siedner MJ, et al
    High residual inflammation despite HIV viral suppression: Lessons learned from real-time adherence monitoring among people with HIV in Africa.
    HIV Med. 2021 Oct 26. doi: 10.1111/hiv.13200.
    PubMed     Abstract available

  12. JILICH D, Skrzat-Klapaczynska A, Fleischhans L, Bursa D, et al
    National strategies for vaccination against COVID-19 in people living with HIV in Central and Eastern European region.
    HIV Med. 2021 Oct 26. doi: 10.1111/hiv.13194.
    PubMed     Abstract available

  13. LARSON D, Won SH, Ganesan A, Maves RC, et al
    Statin usage and cardiovascular risk among people living with HIV in the U.S. Military HIV Natural History Study.
    HIV Med. 2021 Oct 26. doi: 10.1111/hiv.13195.
    PubMed     Abstract available

  14. JONES HT, Samji A, Cope N, Williams J, et al
    What problems associated with ageing are seen in a specialist service for older people living with HIV?
    HIV Med. 2021 Oct 25. doi: 10.1111/hiv.13193.
    PubMed     Abstract available

  15. CORKER E, Lorencatto F, Anderson N, Gobin M, et al
    Acceptability and facilitators of and barriers to point-of-care HIV testing in a homeless-focused service in Gloucestershire: a qualitative evaluation.
    HIV Med. 2021 Oct 24. doi: 10.1111/hiv.13187.
    PubMed     Abstract available

  16. LAJAUNIE R, Cuzin L, Palich R, Makinson A, et al
    No increased risk of Kaposi sarcoma relapse in patients with controlled HIV-1 infection after switching protease inhibitor-based antiretroviral therapy.
    HIV Med. 2021 Oct 19. doi: 10.1111/hiv.13168.
    PubMed     Abstract available

  17. SILVERSTEIN A, Kamiyango W, Villiera J, Peckham-Gregory EC, et al
    Long-term outcomes for children and adolescents with Kaposi sarcoma.
    HIV Med. 2021 Oct 11. doi: 10.1111/hiv.13191.
    PubMed     Abstract available

  18. VASCONCELOS R, Avelino-Silva VI, de Paula IA, Jamal LF, et al
    HIV self-test: a tool to expand test uptake among men who have sex with men who have never been tested for HIV in Sao Paulo, Brazil.
    HIV Med. 2021 Oct 11. doi: 10.1111/hiv.13178.
    PubMed     Abstract available

  19. NITPOLPRASERT C, Anand T, Phanuphak N, Reiss P, et al
    A qualitative study of the impact of coronavirus disease (COVID-19) on psychological and financial wellbeing and engagement in care among men who have sex with men living with HIV in Thailand.
    HIV Med. 2021 Oct 11. doi: 10.1111/hiv.13190.
    PubMed     Abstract available

  20. JONES TPW, Lampe FC, Arenas-Pinto A, Smith C, et al
    Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: cross-sectional and longitudinal analyses.
    HIV Med. 2021 Oct 11. doi: 10.1111/hiv.13156.
    PubMed     Abstract available

  21. BURNS JE, Stirrup O, Waters L, Dunn D, et al
    No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naive adults.
    HIV Med. 2021 Oct 11. doi: 10.1111/hiv.13186.
    PubMed     Abstract available

  22. TUAN JJ, Zapata H, Critch-Gilfillan T, Ryall L, et al
    Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV.
    HIV Med. 2021 Oct 10. doi: 10.1111/hiv.13188.
    PubMed     Abstract available

  23. RICK F, Odoke W, van den Hombergh J, Benzaken AS, et al
    Impact of coronavirus disease (COVID-19) on HIV testing and care provision across four continents.
    HIV Med. 2021 Oct 10. doi: 10.1111/hiv.13180.
    PubMed     Abstract available

  24. BROWN JA, Nsakala BL, Mokhele K, Rakuoane I, et al
    Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study).
    HIV Med. 2021 Oct 10. doi: 10.1111/hiv.13189.
    PubMed     Abstract available

  25. TUFA TB, Fuchs A, Orth HM, Lubke N, et al
    Characterization of HIV-1 drug resistance among patients with failure of second-line combined antiretroviral therapy in central Ethiopia.
    HIV Med. 2021 Oct 7. doi: 10.1111/hiv.13176.
    PubMed     Abstract available

  26. HOVAGUIMIAN F, Martin E, Reinacher M, Rasi M, et al
    Participation, retention and uptake in a multicentre pre-exposure prophylaxis cohort using online, smartphone-compatible data collection.
    HIV Med. 2021 Oct 3. doi: 10.1111/hiv.13175.
    PubMed     Abstract available

  27. CHAPPELL E, Kohns Vasconcelos M, Goodall RL, Galli L, et al
    Children living with HIV in Europe: do migrants have worse treatment outcomes?
    HIV Med. 2021 Oct 1. doi: 10.1111/hiv.13177.
    PubMed     Abstract available

  28. Abstracts of the 18th European AIDS Conference (EACS 2021), Online & London, United Kingdom, October 27-30, 2021.
    HIV Med. 2021;22 Suppl 3:4-309.

    September 2021
  29. GRIMSHAW C, Boyd L, Smith M, Estcourt CS, et al
    Evaluation of an inner city HIV pre-exposure prophylaxis service tailored to the needs of people who inject drugs.
    HIV Med. 2021 Sep 28. doi: 10.1111/hiv.13181.
    PubMed     Abstract available

  30. WONG IKJ, Grulich AE, Poynten IM, Polizzotto MN, et al
    Time trends in cancer incidence in Australian people living with HIV between 1982 and 2012.
    HIV Med. 2021 Sep 28. doi: 10.1111/hiv.13179.
    PubMed     Abstract available

  31. LEE MJ, Snell LB, Douthwaite ST, Fidler S, et al
    Clinical outcomes of patients with and without HIV hospitalized with COVID-19 in England during the early stages of the pandemic: a matched retrospective multi-centre analysis (RECEDE-C19 study).
    HIV Med. 2021 Sep 23. doi: 10.1111/hiv.13174.
    PubMed     Abstract available

  32. MAZZITELLI M, Branca Isabel P, Muramatsu T, Chirwa M, et al
    FRAX assessment in people ageing with HIV.
    HIV Med. 2021 Sep 19. doi: 10.1111/hiv.13170.
    PubMed     Abstract available

  33. BROWN AE, Croxford SE, Nash S, Khawam J, et al
    COVID-19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID-19 pandemic in England.
    HIV Med. 2021 Sep 15. doi: 10.1111/hiv.13167.
    PubMed     Abstract available

  34. BURKE RM, Rickman HM, Singh V, Kalua T, et al
    Same-day antiretroviral therapy initiation for people living with HIV who have tuberculosis symptoms: a systematic review.
    HIV Med. 2021 Sep 15. doi: 10.1111/hiv.13169.
    PubMed     Abstract available

  35. VENKATESH KK, Edmonds A, Westreich D, Dionne-Odom J, et al
    Associations between HIV, antiretroviral therapy and preterm birth in the US Women's Interagency HIV Study, 1995-2018: a prospective cohort.
    HIV Med. 2021 Sep 12. doi: 10.1111/hiv.13171.
    PubMed     Abstract available

  36. BONOU M, Kapelios CJ, Protogerou AD, Mavrogeni S, et al
    Cardiac adiposity as a modulator of cardiovascular disease in HIV.
    HIV Med. 2021 Sep 12. doi: 10.1111/hiv.13166.
    PubMed     Abstract available

  37. CHOI JY, Lui GCY, Liao CT, Yang CJ, et al
    Managing cardiovascular risk in people living with HIV in Asia - where are we now?
    HIV Med. 2021 Sep 7. doi: 10.1111/hiv.13164.
    PubMed     Abstract available

  38. LAHER AE, Paruk F, Venter WDF, Ayeni OA, et al
    Development and internal validation of the HIV In-hospital Mortality Prediction (HIV-IMP) risk score.
    HIV Med. 2021 Sep 5. doi: 10.1111/hiv.13159.
    PubMed     Abstract available

  39. HACHFELD A, Atkinson A, Calmy A, de Tejada BM, et al
    Decrease of condom use in heterosexual couples and its impact on pregnancy rates: the Swiss HIV Cohort Study (SHCS).
    HIV Med. 2021 Sep 2. doi: 10.1111/hiv.13152.
    PubMed     Abstract available

  40. TARAMASSO L, Bonfanti P, Ricci E, Maggi P, et al
    Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade.
    HIV Med. 2021 Sep 2. doi: 10.1111/hiv.13165.
    PubMed     Abstract available

  41. LEAKE DATE HA, Alford K, Hounsome N, Moore D, et al
    Structured medicines reviews in HIV outpatients: a feasibility study (The MOR Study).
    HIV Med. 2021 Sep 1. doi: 10.1111/hiv.13158.
    PubMed     Abstract available

  42. KRAEF C, Bentzon A, Skrahina A, Mocroft A, et al
    Improving healthcare for patients with HIV, tuberculosis and hepatitis C in eastern Europe: a review of current challenges and important next steps.
    HIV Med. 2021 Sep 1. doi: 10.1111/hiv.13163.
    PubMed     Abstract available

    August 2021
  43. SPARKS E, Zorzela L, Necyk C, Hughes C, et al
    Study of natural product adverse events in adult HIV-infected patients in Canada.
    HIV Med. 2021 Aug 25. doi: 10.1111/hiv.13155.
    PubMed     Abstract available

  44. WHITLOCK GG, Protopapas K, Bernardino JI, Imaz A, et al
    Chems4EU: chemsex use and its impacts across four European countries in HIV-positive men who have sex with men attending HIV services.
    HIV Med. 2021 Aug 25. doi: 10.1111/hiv.13160.
    PubMed     Abstract available

  45. SANDERS EJ, Agutu C, van der Elst E, Hassan A, et al
    Effect of an opt-out point-of-care HIV-1 nucleic acid testing intervention to detect acute and prevalent HIV infection in symptomatic adult outpatients and reduce HIV transmission in Kenya: a randomized controlled trial.
    HIV Med. 2021 Aug 25. doi: 10.1111/hiv.13157.
    PubMed     Abstract available

  46. ANIKPO I, Agovi AM, Cvitanovich MJ, Lonergan F, et al
    The data-collection on adverse effects of anti-HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV.
    HIV Med. 2021 Aug 19. doi: 10.1111/hiv.13147.
    PubMed     Abstract available

  47. CHALOUNI M, Pol S, Sogni P, Fontaine H, et al
    Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
    HIV Med. 2021 Aug 17. doi: 10.1111/hiv.13153.
    PubMed     Abstract available

  48. PINCUS KJ, Blackman AL, Suen SY, Devabhakthuni S, et al
    Statin gap in patients living with HIV: assessing dose appropriateness.
    HIV Med. 2021 Aug 8. doi: 10.1111/hiv.13150.
    PubMed     Abstract available

  49. FRANGE P, Blanche S, Veber F, Avettand-Fenoel V, et al
    Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance.
    HIV Med. 2021 Aug 8. doi: 10.1111/hiv.13154.
    PubMed     Abstract available

  50. Abstracts of the 5th Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH), Virtual, 19-21 April 2021.
    HIV Med. 2021;22 Suppl 2:3-126.

    July 2021
  51. ROBERTS O, Kinvig H, Owen A, Lamorde M, et al
    In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel.
    HIV Med. 2021 Jul 30. doi: 10.1111/hiv.13136.
    PubMed     Abstract available

  52. LAWAL IO, Orunmuyi AT, Popoola GO, Mokoala KMG, et al
    Immune reconstitution inflammatory syndrome-associated Graves disease in HIV-infected patients: clinical characteristics and response to radioactive iodine therapy.
    HIV Med. 2021 Jul 30. doi: 10.1111/hiv.13148.
    PubMed     Abstract available

  53. DIEZ C, Del Romero-Raposo J, Mican R, Lopez JC, et al
    COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study.
    HIV Med. 2021 Jul 29. doi: 10.1111/hiv.13145.
    PubMed     Abstract available

  54. GIROMETTI N, Delpech V, McCormack S, Khawam J, et al
    The success of HIV combination prevention: The Dean Street model.
    HIV Med. 2021 Jul 29. doi: 10.1111/hiv.13149.
    PubMed     Abstract available

  55. FABBIANI M, Rossetti B, Ciccullo A, Oreni L, et al
    Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort.
    HIV Med. 2021 Jul 27. doi: 10.1111/hiv.13146.
    PubMed     Abstract available

  56. OKHAI H, Sabin CA, Haag K, Sherr L, et al
    Menopausal status, age and management among women living with HIV in the UK.
    HIV Med. 2021 Jul 26. doi: 10.1111/hiv.13138.
    PubMed     Abstract available

  57. SQUILLACE N, Bernasconi DP, Lapadula G, Soria A, et al
    HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation.
    HIV Med. 2021 Jul 22. doi: 10.1111/hiv.13143.
    PubMed     Abstract available

  58. BOEKE CE, Khan S, Walsh FJ, Lejeune C, et al
    Longitudinal analysis of client appointment adherence under Universal Test and Treat strategy: A stepped-wedge trial.
    HIV Med. 2021 Jul 22. doi: 10.1111/hiv.13144.
    PubMed     Abstract available

  59. SHARMA I
    Interrogating the impact of combination antiretroviral therapies on HIV-associated neurocognitive disorders.
    HIV Med. 2021 Jul 21. doi: 10.1111/hiv.13142.
    PubMed     Abstract available

  60. TORRES B, Guardo AC, Squarcia M, Diaz A, et al
    Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial.
    HIV Med. 2021 Jul 20. doi: 10.1111/hiv.13114.
    PubMed     Abstract available

  61. KIM JH, Noh J, Kim W, Seong H, et al
    Trends of age-related non-communicable diseases in people living with HIV and comparison with uninfected controls: A nationwide population-based study in South Korea.
    HIV Med. 2021 Jul 14. doi: 10.1111/hiv.13139.
    PubMed     Abstract available

  62. LEI JJH, Pereira B, Moyle G, Boffito M, et al
    The benefits of tenofovir discontinuation with or without bisphosphonate therapy in osteoporotic people living with HIV.
    HIV Med. 2021 Jul 13. doi: 10.1111/hiv.13137.
    PubMed     Abstract available

  63. WOLDESENBET SA, Kufa-Chakezha T, Lombard C, Manda S, et al
    Coverage of maternal viral load monitoring during pregnancy in South Africa: Results from the 2019 national Antenatal HIV Sentinel Survey.
    HIV Med. 2021 Jul 1. doi: 10.1111/hiv.13126.
    PubMed     Abstract available

  64. CHALOUNI M, Wittkop L, Bani-Sadr F, Lacombe K, et al
    Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants.
    HIV Med. 2021 Jul 1. doi: 10.1111/hiv.13127.
    PubMed     Abstract available

  65. CRAWFORD D, Allan B, Cogle A, Brown G, et al
    Client-led care in HIV: perspectives from community and practice.
    HIV Med. 2021;22 Suppl 1:3-14.
    PubMed     Abstract available

    June 2021
  66. LE XQ, Liu DP, Chen J, Gong ZY, et al
    Urinary biomarkers of early renal injury in antiretroviral-naive HIV-positive persons in Shanghai, China: comparison with the general population.
    HIV Med. 2021 Jun 10. doi: 10.1111/hiv.13123.
    PubMed     Abstract available

  67. MURRAY MM, Lin J, Buros Stein A, Wilcox ML, et al
    Relationship of polypharmacy to HIV RNA suppression in people aged >/= 50 years living with HIV.
    HIV Med. 2021 Jun 2. doi: 10.1111/hiv.13122.
    PubMed     Abstract available

  68. ZHABOKRITSKY A, Szadkowski L, Burchell AN, Cooper C, et al
    Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC).
    HIV Med. 2021 Jun 1. doi: 10.1111/hiv.13125.
    PubMed     Abstract available

    May 2021
  69. KIM J, Nam HJ, Kang SJ, Jung SI, et al
    Integrase strand transfer inhibitor treatment does not increase the incidence of immune reconstitution inflammatory syndrome in HIV-infected Koreans.
    HIV Med. 2021 May 28. doi: 10.1111/hiv.13117.
    PubMed     Abstract available

  70. SCHULZ CA, Mavarani L, Reinsch N, Albayrak-Rena S, et al
    Prediction of future cardiovascular events by Framingham, SCORE and asCVD risk scores is less accurate in HIV-positive individuals from the HIV-HEART Study compared with the general population.
    HIV Med. 2021 May 24. doi: 10.1111/hiv.13124.
    PubMed     Abstract available

  71. MMASA KN, Powis K, Sun S, Makhema J, et al
    Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir- than with efavirenz-based antiretroviral therapy.
    HIV Med. 2021 May 18. doi: 10.1111/hiv.13120.
    PubMed     Abstract available

  72. REGO DE FIGUEIREDO I, Branco Ferrao J, Dias S, Vieira Alves R, et al
    Tuberculosis infection in HIV vs. non-HIV patients.
    HIV Med. 2021 May 17. doi: 10.1111/hiv.13119.
    PubMed     Abstract available

  73. ALBASANZ-PUIG A, Suanzes P, Esperalba J, Fernandez C, et al
    Low frequency of cytomegalovirus (CMV) disease despite high prevalence of CMV viraemia in patients with advanced HIV infection: a clinical and immunological 48-week follow-up study.
    HIV Med. 2021 May 17. doi: 10.1111/hiv.13115.
    PubMed     Abstract available

  74. VORA J, Velhal S, Sinha S, Patel V, et al
    Bioactive phytocompound mulberroside C and endophytes of Morus alba as potential inhibitors of HIV-1 replication: a mechanistic evaluation.
    HIV Med. 2021 May 14. doi: 10.1111/hiv.13116.
    PubMed     Abstract available

  75. GILL MJ, Powell M, Vu Q, Krentz HB, et al
    Economic impact on direct healthcare costs of missing opportunities for diagnosing HIV within healthcare settings.
    HIV Med. 2021 May 12. doi: 10.1111/hiv.13121.
    PubMed     Abstract available

  76. FAN X, Fang J, Wu X, Poulsen K, et al
    Effect of HIV infection on pre- and post-liver transplant mortality in patients with organ failure.
    HIV Med. 2021 May 8. doi: 10.1111/hiv.13113.
    PubMed     Abstract available

  77. BURNS JE, Stohr W, Kinloch-De Loes S, Fox J, et al
    Tolerability of four-drug antiretroviral combination therapy in primary HIV-1 infection.
    HIV Med. 2021 May 8. doi: 10.1111/hiv.13118.
    PubMed     Abstract available

  78. PHALANE E, Fourie C, Schutte AE, Kruger IM, et al
    Arterial structure and function in Africans with HIV for > 5 years: longitudinal relationship with endothelial activation and cardiovascular risk markers.
    HIV Med. 2021 May 5. doi: 10.1111/hiv.13111.
    PubMed     Abstract available

  79. HOWARTH AR, Apea V, Michie S, Morris S, et al
    The association between use of chemsex drugs and HIV clinic attendance among gay and bisexual men living with HIV in London.
    HIV Med. 2021 May 5. doi: 10.1111/hiv.13103.
    PubMed     Abstract available

  80. ASAD H, Collins IJ, Goodall RL, Crichton S, et al
    Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UK.
    HIV Med. 2021 May 3. doi: 10.1111/hiv.13096.
    PubMed     Abstract available

    April 2021
  81. RICHARDSON D, Nichols K, Pickering A, Devlin J, et al
    Transitioning from HIV post-exposure prophylaxis to pre-exposure prophylaxis in men who have sex with men.
    HIV Med. 2021 Apr 30. doi: 10.1111/hiv.13112.

  82. JANSEN N, Daniels C, Sunil T, Xu X, et al
    Factors associated with erectile dysfunction diagnosis in men with HIV infection: a case-control study.
    HIV Med. 2021 Apr 25. doi: 10.1111/hiv.13107.
    PubMed     Abstract available

  83. KOVARI H, Surial B, Tarr PE, Cavassini M, et al
    Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
    HIV Med. 2021 Apr 20. doi: 10.1111/hiv.13106.
    PubMed     Abstract available

  84. PATEL PG, Keen P, McManus H, Duck T, et al
    Increased targeted HIV testing and reduced undiagnosed HIV infections among gay and bisexual men.
    HIV Med. 2021 Apr 19. doi: 10.1111/hiv.13102.
    PubMed     Abstract available

  85. EZEAMAMA AE, Zalwango SK, Sikorskii A, Tuke R, et al
    In utero and peripartum antiretroviral exposure as predictor of cognition in 6- to 10-year-old HIV-exposed Ugandan children - a prospective cohort study.
    HIV Med. 2021 Apr 16. doi: 10.1111/hiv.13094.
    PubMed     Abstract available

  86. SAUMOY M, Di Yacovo S, Perez S, Sanchez-Quesada JL, et al
    Carotid atherosclerosis in virologically suppressed HIV patients: comparison with a healthy sample and prediction by cardiovascular risk equations.
    HIV Med. 2021 Apr 5. doi: 10.1111/hiv.13093.
    PubMed     Abstract available

    March 2021
  87. LAHER AE, Paruk F, Venter W, Ayeni OA, et al
    Predictors of in-hospital mortality among HIV-positive patients presenting with an acute illness to the emergency department.
    HIV Med. 2021 Mar 31. doi: 10.1111/hiv.13097.
    PubMed     Abstract available

  88. FOKAM J, Takou D, Njume D, Pabo W, et al
    Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon.
    HIV Med. 2021 Mar 31. doi: 10.1111/hiv.13095.
    PubMed     Abstract available

  89. NKUIZE M, Vanderpas J, Buset M, Delforge M, et al
    Failure to eradicate Helicobacter pylori infection is more frequent among HIV-positive patients.
    HIV Med. 2021 Mar 25. doi: 10.1111/hiv.13083.
    PubMed     Abstract available

  90. MASSAH G, Zhang W, Birungi J, Nanfuka M, et al
    Gender disparities operate in opposite directions for hospitalizations and mortality among individuals receiving long-term ART in rural Uganda.
    HIV Med. 2021 Mar 17. doi: 10.1111/hiv.13080.
    PubMed     Abstract available

  91. CHAN P, Colby DJ, Kroon E, Sacdalan C, et al
    Clinical and laboratory impact of concomitant syphilis infection during acute HIV.
    HIV Med. 2021 Mar 17. doi: 10.1111/hiv.13079.
    PubMed     Abstract available

  92. KANDA N, Okamoto K, Okumura H, Mieno M, et al
    Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
    HIV Med. 2021 Mar 15. doi: 10.1111/hiv.13061.
    PubMed     Abstract available

  93. D'SOUZA G, Benning L, Stosor V, Witt MD, et al
    The shifting picture of HIV treatment, comorbidity and substance use among US MSM living with HIV.
    HIV Med. 2021 Mar 10. doi: 10.1111/hiv.13082.
    PubMed     Abstract available

  94. ASCHER SB, Scherzer R, Estrella MM, Muiru AN, et al
    Kidney tubule health scores and their associations with incident CKD in women living with HIV.
    HIV Med. 2021 Mar 9. doi: 10.1111/hiv.13081.
    PubMed     Abstract available

    February 2021
  95. JESPERSEN NA, Axelsen F, Dollerup J, Norgaard M, et al
    The burden of non-communicable diseases and mortality in people living with HIV (PLHIV) in the pre-, early- and late-HAART era.
    HIV Med. 2021 Feb 28. doi: 10.1111/hiv.13077.
    PubMed     Abstract available

  96. PUNEKAR YS, Parks D, Joshi M, Kaur S, et al
    Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.
    HIV Med. 2021 Feb 2. doi: 10.1111/hiv.13050.
    PubMed     Abstract available

  97. YANAVICH C, Pacheco AG, Cardoso SW, Nunes EP, et al
    Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV.
    HIV Med. 2021 Feb 2. doi: 10.1111/hiv.13060.
    PubMed     Abstract available

  98. CROXFORD S, Burns F, Copas A, Yin Z, et al
    Trends and predictors of linkage to HIV outpatient care following diagnosis in the era of expanded testing in England, Wales and Northern Ireland: Results of a national cohort study.
    HIV Med. 2021 Feb 2. doi: 10.1111/hiv.13078.
    PubMed     Abstract available

    January 2021
  99. BOOTON RD, Ong JJ, Lee A, Liu A, et al
    Modelling the impact of an HIV testing intervention on HIV transmission among men who have sex with men in China.
    HIV Med. 2021 Jan 28. doi: 10.1111/hiv.13063.
    PubMed     Abstract available

  100. ARMENIA D, Bouba Y, Gagliardini R, Fabeni L, et al
    Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice.
    HIV Med. 2021 Jan 21. doi: 10.1111/hiv.13062.
    PubMed     Abstract available

  101. NOCELLA C, Mezzaroma I, Cammisotto V, Castellani V, et al
    Lipopolysaccharide induces platelet activation in HIV patients: the role of different viral load patterns.
    HIV Med. 2021 Jan 10. doi: 10.1111/hiv.13059.
    PubMed     Abstract available

  102. XU X, Lin H, Chen X, Zhu B, et al
    Differences in hypertension and prehypertension among people living with and without HIV in China: role of HIV infection and antiretroviral therapy.
    HIV Med. 2021 Jan 9. doi: 10.1111/hiv.13040.
    PubMed     Abstract available

  103. HORN C, Augustin M, Ercanoglu MS, Heger E, et al
    HIV DNA reservoir and elevated PD-1 expression of CD4 T-cell subsets particularly persist in the terminal ileum of HIV-positive patients despite cART.
    HIV Med. 2021 Jan 9. doi: 10.1111/hiv.13031.
    PubMed     Abstract available

  104. JABLONOWSKA E, Szetela B, Bielecki M, Horban A, et al
    Acquired immune deficiency syndrome (AIDS) and late presentation in Poland - data from Test and Keep in Care (TAK) Polska project.
    HIV Med. 2021 Jan 6. doi: 10.1111/hiv.13041.
    PubMed     Abstract available

  105. British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019.
    HIV Med. 2021;22:73.

    December 2020
  106. HOFFMANN C, Casado JL, Harter G, Vizcarra P, et al
    Immune deficiency is a risk factor for severe COVID-19 in people living with HIV.
    HIV Med. 2020 Dec 27. doi: 10.1111/hiv.13037.
    PubMed     Abstract available

  107. GONZALEZ-SERNA A, Macias J, Palacios R, Gomez-Ayerbe C, et al
    Incidence of recently acquired hepatitis C virus infection among HIV-infected patients in southern Spain.
    HIV Med. 2020 Dec 26. doi: 10.1111/hiv.13039.
    PubMed     Abstract available

  108. BAXTER JD, Dunn D, Tostevin A, Marvig RL, et al
    Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.
    HIV Med. 2020 Dec 25. doi: 10.1111/hiv.13038.
    PubMed     Abstract available

  109. REICHMUTH ML, Chaudron SE, Bachmann N, Nguyen H, et al
    Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission.
    HIV Med. 2020 Dec 25. doi: 10.1111/hiv.13030.
    PubMed     Abstract available

  110. MCLEOD A, Hutchinson SJ, Smith S, Leen C, et al
    Increased case-finding and uptake of direct-acting antiviral treatment essential for micro-elimination of hepatitis C among people living with HIV: a national record linkage study.
    HIV Med. 2020 Dec 17. doi: 10.1111/hiv.13032.
    PubMed     Abstract available

  111. FIGUEROA MI, Camiro-Zuniga A, Belaunzaran-Zamudio PF, Sierra Madero J, et al
    The effect of protease inhibitor-based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART-naive patients with HIV-infection.
    HIV Med. 2020 Dec 17. doi: 10.1111/hiv.13008.
    PubMed     Abstract available

  112. BOGORODSKAYA M, Lyass A, Mahoney TF, Borowsky LH, et al
    Utilization of absolute monocyte counts to predict cardiovascular events in people living with HIV.
    HIV Med. 2020 Dec 8. doi: 10.1111/hiv.13018.
    PubMed     Abstract available

  113. TIAN Q, Si J, Jiang F, Xu R, et al
    Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection.
    HIV Med. 2020 Dec 4. doi: 10.1111/hiv.13013.
    PubMed     Abstract available

  114. HIREMATH PG, Bhondoekhan F, Haberlen SA, Ashikaga H, et al
    Testosterone use and shorter electrocardiographic QT interval duration in men living with and without HIV.
    HIV Med. 2020 Dec 3. doi: 10.1111/hiv.13029.
    PubMed     Abstract available

  115. CHADWICK DR, Sutherland RK, Raffe S, Pool E, et al
    British HIV Association guidelines on the management of opportunistic infection in people living with HIV: the clinical management of gastrointestinal opportunistic infections 2020.
    HIV Med. 2020;21 Suppl 5:1-19.

  116. PALFREEMAN A, Sullivan A, Rayment M, Waters L, et al
    British HIV Association/British Association for Sexual Health and HIV/British Infection Association adult HIV testing guidelines 2020.
    HIV Med. 2020;21 Suppl 6:1-26.

  117. LIU JY, Sun LQ, Hou YY, Wang LF, et al
    Barriers to early diagnosis and treatment of severely immunosuppressed patients with HIV-1 infection: A quantitative and qualitative study.
    HIV Med. 2020;21:708-717.
    PubMed     Abstract available

  118. HU W, Jiao YM, Wang FS
    Snapshot of clinical studies on people living with HIV in China.
    HIV Med. 2020;21:681-682.

  119. YING RS, Le T, Cai WP, Li YR, et al
    Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017.
    HIV Med. 2020;21:729-738.
    PubMed     Abstract available

  120. ZHAO Y, Han MJ, Gan XM, Ma Y, et al
    Characteristics and viral suppression among people living with HIV from the National Free Antiretroviral Therapy Programme, 2019.
    HIV Med. 2020;21:701-707.
    PubMed     Abstract available

  121. QI TK, Chen J, Zhang RF, Liu L, et al
    A retrospective cohort study of early mortality among patients with HIV/TB co-infection in Shanghai municipality.
    HIV Med. 2020;21:739-746.
    PubMed     Abstract available

  122. ZHANG C, Hu W, Jin JH, Zhou MJ, et al
    The role of CD8 T cells in controlling HIV beyond the antigen-specific face.
    HIV Med. 2020;21:692-700.
    PubMed     Abstract available

  123. LIU A, Zhang L, Zhang X, Zhang HW, et al
    Delayed seroreversion of specifical antibody against HIV in HIV-exposed infants: A retrospective cohort study.
    HIV Med. 2020;21:718-721.
    PubMed     Abstract available

  124. LIN L, Li TS
    Multidisciplinary collaborative integrated management of increasingly prominent HIV complications in the post-cART era.
    HIV Med. 2020;21:683-691.
    PubMed     Abstract available

  125. LI JH, Ma J, Kang W, Wang CF, et al
    The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV-infected patients on suppressive antiretroviral therapy.
    HIV Med. 2020;21:747-757.
    PubMed     Abstract available

  126. JIANG TY, Hou JH, Su B, Zhang T, et al
    Demographic and clinical factors associated with immune reconstitution in HIV/HBV co-infected and HIV mono-infected patients: a retrospective cohort study.
    HIV Med. 2020;21:722-728.
    PubMed     Abstract available

    November 2020
  127. HSU R, Brunet L, Fusco J, Beyer A, et al
    Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score.
    HIV Med. 2020 Nov 28. doi: 10.1111/hiv.13019.
    PubMed     Abstract available

  128. SIVARAJ V, Cliff P, Douthwaite S, Smith M, et al
    Pneumocystis jirovecii pneumonia PCR test on upper respiratory tract swab.
    HIV Med. 2020 Nov 23. doi: 10.1111/hiv.13014.
    PubMed     Abstract available

  129. BENTZON AK, Panteleev A, Mitsura V, Borodulina E, et al
    Healthcare delivery for HIV-positive people with tuberculosis in Europe.
    HIV Med. 2020 Nov 20. doi: 10.1111/hiv.13016.
    PubMed     Abstract available

  130. HAN WM, Jiamsakul A, Jantarapakde J, Yunihastuti E, et al
    Association of body mass index with immune recovery, virological failure and cardiovascular disease risk among people living with HIV.
    HIV Med. 2020 Nov 17. doi: 10.1111/hiv.13017.
    PubMed     Abstract available

  131. CUI Z, Huang H, Zhang T, Yu Z, et al
    Low awareness of and willingness to use PrEP in the Chinese YMSM: An alert in YMSM HIV prevention.
    HIV Med. 2020 Nov 16. doi: 10.1111/hiv.12990.
    PubMed     Abstract available

  132. SANMARTI M, Meyer AC, Jaen A, Robertson K, et al
    HIV-associated neurocognitive impairment in stable people living with HIV on ART in rural Tanzania.
    HIV Med. 2020 Nov 15. doi: 10.1111/hiv.12979.
    PubMed     Abstract available

  133. TRICKEY A, Stone J, Semchuk N, Saliuk T, et al
    Is contact between men who have sex with men and non-governmental organizations providing harm reduction associated with improved HIV outcomes?
    HIV Med. 2020 Nov 12. doi: 10.1111/hiv.13010.
    PubMed     Abstract available

  134. SARFO FS, Norman B, Nichols M, Appiah L, et al
    Prevalence and incidence of pre-diabetes and diabetes mellitus among people living with HIV in Ghana: Evidence from the EVERLAST Study.
    HIV Med. 2020 Nov 10. doi: 10.1111/hiv.13007.
    PubMed     Abstract available

  135. HANTTU A, Kauppinen KJ, Kivela P, Ollgren J, et al
    Prevalence of obesity and disturbances in glucose homeostasis in HIV-infected subjects and general population - missed diagnoses of diabetes?
    HIV Med. 2020 Nov 9. doi: 10.1111/hiv.13009.
    PubMed     Abstract available

  136. CHOUDHURY B, Brown J, Ransy DG, Brophy J, et al
    Endothelial activation is associated with intestinal epithelial injury, systemic inflammation and treatment regimen in children living with vertically acquired HIV-1 infection.
    HIV Med. 2020 Nov 5. doi: 10.1111/hiv.13012.
    PubMed     Abstract available

  137. BEANLAND A, Alagaratnam J, Goffe C, Bailey A, et al
    Objective and subjective rapid frailty screening tools in people with HIV.
    HIV Med. 2020 Nov 5. doi: 10.1111/hiv.12988.
    PubMed     Abstract available

  138. ROSS J, Jiamsakul A, Kumarasamy N, Azwa I, et al
    Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific.
    HIV Med. 2020 Nov 5. doi: 10.1111/hiv.13006.
    PubMed     Abstract available

  139. MORKPHROM E, Ratanasuwan W, Sittironnarit G, Rattanaumpawan P, et al
    Non-disclosure of HIV serostatus to sexual partners: Prevalence, risk factors and clinical impact in patients with HIV.
    HIV Med. 2020 Nov 3. doi: 10.1111/hiv.13005.
    PubMed     Abstract available

  140. PODA A, Kabore NF, Malateste K, De Rekeneire N, et al
    Validation of the D:A:D chronic kidney disease risk score in people living with HIV: the IeDEA West Africa Cohort Collaboration.
    HIV Med. 2020 Nov 3. doi: 10.1111/hiv.12982.
    PubMed     Abstract available

  141. TO KW, Lee SS
    A review of reported cases of HIV pre-exposure prophylaxis failure with resultant breakthrough HIV infections.
    HIV Med. 2020 Nov 3. doi: 10.1111/hiv.12989.
    PubMed     Abstract available

  142. Abstracts of the 26th Annual Conference of the British HIV Association (BHIVA), Digital Conference, 22nd-24th November 2020.
    HIV Med. 2020;21 Suppl 4:3-74.

    October 2020
  143. PAUL G, Wesselmann J, Adzic D, Malin JJ, et al
    Predictors of serofast state after treatment for early syphilis in HIV-infected patients.
    HIV Med. 2020 Oct 30. doi: 10.1111/hiv.12985.
    PubMed     Abstract available

  144. FREGUJA R, Bamford A, Zanchetta M, Del Bianco P, et al
    Long-term clinical, virological and immunological outcomes following planned treatment interruption in HIV-infected children.
    HIV Med. 2020 Oct 29. doi: 10.1111/hiv.12986.
    PubMed     Abstract available

  145. FERNANDEZ I, de Lazzari E, Inciarte A, Diaz-Brito V, et al
    Network meta-analysis of post-exposure prophylaxis randomized clinical trials.
    HIV Med. 2020 Oct 27. doi: 10.1111/hiv.12964.
    PubMed     Abstract available

  146. MCALLISTER S, van Asten H, Anglemyer A, Crengle S, et al
    Cascade of care of people diagnosed with HIV in New Zealand between 2006 and 2017.
    HIV Med. 2020 Oct 27. doi: 10.1111/hiv.12983.
    PubMed     Abstract available

  147. KIRWAN PD, Hibbert M, Kall M, Nambiar K, et al
    HIV prevalence and HIV clinical outcomes of transgender and gender-diverse people in England.
    HIV Med. 2020 Oct 26. doi: 10.1111/hiv.12987.
    PubMed     Abstract available

  148. AUNG HL, Bloch M, Vincent T, Quan D, et al
    Cognitive ageing is premature among a community sample of optimally treated people living with HIV.
    HIV Med. 2020 Oct 21. doi: 10.1111/hiv.12980.
    PubMed     Abstract available

  149. GAZZOLA L, Tagliaferri G, De Bona A, Mondatore D, et al
    Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?
    HIV Med. 2020 Oct 21. doi: 10.1111/hiv.12984.
    PubMed     Abstract available

  150. QUAH SP, McIntyre M, Wood A, Mc Mullan K, et al
    Once-daily raltegravir with tenofovir disoproxil/emtricitabine as HIV post-exposure prophylaxis following sexual exposure.
    HIV Med. 2020 Oct 16. doi: 10.1111/hiv.12938.

  151. SCHUETTFORT G, Boekenkamp L, Cabello A, Cotter AG, et al
    Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors.
    HIV Med. 2020 Oct 13. doi: 10.1111/hiv.12962.
    PubMed     Abstract available

  152. WENGER DS, Triplette M, Shahrir S, Akgun KM, et al
    Associations of marijuana with markers of chronic lung disease in people living with HIV.
    HIV Med. 2020 Oct 6. doi: 10.1111/hiv.12966.
    PubMed     Abstract available

  153. VAUGHAN J, Perner Y, Mayne E, Wiggill T, et al
    Plasmablastic lymphoma in Johannesburg, South Africa, in the era of widescale antiretroviral therapy use.
    HIV Med. 2020 Oct 6. doi: 10.1111/hiv.12965.
    PubMed     Abstract available

  154. BALAYAN T, Begovac J, Skrzat-Klapaczynska A, Aho I, et al
    Where are we with pre-exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group.
    HIV Med. 2020 Oct 5. doi: 10.1111/hiv.12960.
    PubMed     Abstract available

  155. ALMEIDA F, Macedo A, Trigo D, Abreu M, et al
    Neurocognitive evaluation using the International HIV Dementia Scale (IHDS) and Montreal Cognitive Assessment Test (MoCA) in an HIV-2 population.
    HIV Med. 2020 Oct 4. doi: 10.1111/hiv.12963.
    PubMed     Abstract available

  156. BLOCH M, John M, Smith D, Rasmussen TA, et al
    Managing HIV-associated inflammation and ageing in the era of modern ART.
    HIV Med. 2020;21 Suppl 3:2-16.
    PubMed     Abstract available

  157. IBRAHIM F, Campbell L, Bailey AC, Stockwell S, et al
    Estimated glomerular filtration rate slopes on tenofovir alafenamide.
    HIV Med. 2020;21:607-612.
    PubMed     Abstract available

  158. DRAVID A, Betha TP, Sharma AK, Gawali R, et al
    Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhi
    HIV Med. 2020;21:578-587.
    PubMed     Abstract available

    September 2020
  159. IBRAHIM F, Samarawickrama A, Hamzah L, Vincent R, et al
    Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.
    HIV Med. 2020 Sep 27. doi: 10.1111/hiv.12961.
    PubMed     Abstract available

  160. BASIL RC, Brown TT, Haberlen S, Rubin LH, et al
    The relationship between diabetes and depressive symptoms in men with or at risk of HIV infection.
    HIV Med. 2020 Sep 24. doi: 10.1111/hiv.12958.
    PubMed     Abstract available

  161. BORGHETTI A, Ciccullo A, Lombardi F, Baldin G, et al
    Transmitted drug resistance to NRTIs and risk of virological failure in naive patients treated with integrase inhibitors.
    HIV Med. 2020 Sep 23. doi: 10.1111/hiv.12956.
    PubMed     Abstract available

  162. ADAMS JL, Murray M, Patel N, Sawkin MT, et al
    Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study.
    HIV Med. 2020 Sep 23. doi: 10.1111/hiv.12959.
    PubMed     Abstract available

  163. KORTEN V, Ay U, Hari E, Tigen Tukenmez E, et al
    Prevalence of HIV-associated neurocognitive disorder (HAND) in Turkey and assessment of Addenbrooke's Cognitive Examination Revised (ACE-R) test as a screening tool.
    HIV Med. 2020 Sep 23. doi: 10.1111/hiv.12957.
    PubMed     Abstract available

  164. RYOM L, Cotter A, De Miguel R, Beguelin C, et al
    2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
    HIV Med. 2020 Sep 3. doi: 10.1111/hiv.12878.
    PubMed     Abstract available

  165. GIROMETTI N, Lander F, McOwan A, Nwokolo N, et al
    Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort.
    HIV Med. 2020 Sep 1. doi: 10.1111/hiv.12900.
    PubMed     Abstract available

    June 2020
  166. GANTNER P, Allavena C, Duvivier C, Cabie A, et al
    Post-exposure prophylaxis completion and condom use in the context of potential sexual exposure to HIV.
    HIV Med. 2020 Jun 17. doi: 10.1111/hiv.12880.
    PubMed     Abstract available

    February 2020
  167. SCHWARZE-ZANDER C, Piduhn H, Boesecke C, Schlabe S, et al
    Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?
    HIV Med. 2020 Feb 17. doi: 10.1111/hiv.12840.
    PubMed     Abstract available

    January 2020
  168. STIRRUP OT, Asboe D, Pozniak A, Sabin CA, et al
    Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
    HIV Med. 2020 Jan 11. doi: 10.1111/hiv.12829.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.